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Secondary leukemia occurs long after remission of the primary
tumor with a history of chemo and radiation therapy; how-
ever, the mechanism of secondary leukemogenesis is not fully
understood.
1 In this study, we demonstrate cases of secondary
T-cell leukemia in mice after complete regression of xenograft
primary glioblastoma independent of chemo and radiotherapy.
Recently, antiangiogenic therapy, often in combination with
conventional chemotherapy, has been clinically validated for
solid tumors.
2 Vascular endothelial growth factors (VEGFs) and
their receptors (VEGFRs) are major regulators of angiogenesis;
3
indeed, a monoclonal anti-VEGF antibody (bevacizumab) and
small molecular weight inhibitors of VEGFRs (sorafenib and
sunitinib) have improved the therapeutic indexes of advanced
malignancies, including the increase in disease-free survival in
breast cancer, colorectal cancer, non-small cell lung carcinoma,
renal cell carcinoma, hepatocellular carcinoma and glioblastoma.
However, antitumor effect of anti-VEGF antibody and VEGF
receptor inhibitors concomitant with increased invasiveness, and
distant metastasis have been reported using preclinical cancer
models.
4 In addition, high-grade glioma patients following
treatments with anti-VEGF antibody in combination with irinote-
can demonstrated an effective response by the primary tumor, but
also a high rate of distant tumor progression including tumor
inﬁltration and vascular co-option.
5 We previously reported that
long-term hypoxia and nutrient starvation double-deprivation
cycles increased cellular migration, invasion and distant metastasis
in a murine cancer model, suggesting that this extreme tumor
microenvironment could be a mechanism of the tumor aggres-
siveness following antiangiogenic therapy.
6
Glioblastoma is the most common brain tumor in adults and is
often rapidly fatal with median survival of less than a year from
diagnosis.
7 In contrast, brain tumors in fetal to young individuals
may achieve complete regression of the primary tumor with
surgical resection along with standard chemotherapy and/or
radiotherapy. A major clinical problem of brain tumors in fetal
and young individuals can be recurrence of the primary tumor
or development of secondary leukemia years after remission of
the primary tumor. We hypothesized that non-tumorigenic
human glioblastoma (T98G) cells exposed to hypoxia and
nutrient starvation may become aggressive and also affect host
cells, causing leukemia.
On this basis, we developed a cell culture system to maintain
cells under hypoxia and nutrition starvation double deprivation-
stress (DDS) cycles, which at least partially reﬂected in vitro the
hypoxic and nutrient-starved tumor microenvironment under
antiangiogenesis therapy.
6 Using this system, we generated
T98G-DDS10 cells exposed to 10 or more cycles of hypoxia and
nutrient deprivation stress cycles (Figure 1a), because most
cancer cells including T98G cells cannot be maintained under
the prolonged hypoxia and nutrient starvation DDS for longer
than 72h in vitro (Figure 1b).
To examine whether hypoxia and nutrient starvation facilitate
the induction of tumorigenicity in non-tumorigenic T98G cells,
1 10
7 of T98G-DDS10 cells were subcutaneously inoculated
into BALB/c nu/nu nude mice (n¼5) along with the original
T98G cell xenograft in control mice (n¼5). T98G-DDS10 tumor
xenograft mice demonstrated initial formation of tumors (3/5),
but not original T98G tumor xenograft mice (0/5) (Figure 1c).
The T98G-DDS10 primary tumor showed complete regression
within 2 weeks. We examined whether T98G-DDS10 xenograft
cells induced recurrence of the tumor or affected host cells
to induce leukemia after remission of the primary tumor.
T98G-DDS10 xenograft mice were disease free for 1 year, but
suddenly, around day 365–375 after inoculation of T98G-
DDS10, these three mice almost simultaneously lapsed into a
cachexic condition with an enlarged spleen, liver, lymph node
and invasion of immature lymphocytes in hemorrhagic ascites of
the abdominal cavity (Figure 1d, Supplementary Figure 1).
Quantitative real-time PCR was performed using human-speciﬁc
primers against hb-actin and human glial ﬁbrillary acidic protein
(hGFAP) for the detection of T98G glioblastoma cells. In
addition, mouse-speciﬁc primers against T-cell pan-marker
mCD3 and mouse B-cell pan-marker mCD19 were used for
the detection of mouse-derived secondary leukemia in the
spleen and liver tissue specimens of T98G-DDS10 xenograft
mice (Supplementary Table 1). As shown in Figure 2a, signiﬁ-
cant upregulation of mCD3 mRNA levels was observed, but hb-
actin and hGFAP mRNA was not detected in the spleen or liver
tissues of mice with T98G-DDS10 xenograft. The mRNA of
mCD19, a B-cell marker, was found at similar levels in the
spleens of T98G and T98G-DDS10 xenograft mice, and was
markedly low in the livers of these mice compared with normal
spleens (positive controls), suggesting that mCD19 expression in
leukemic cells is negative at the mRNA level (Figure 2a).
Histological examination by hematoxylin-eosin (HE) staining
showed massive invasion of leukemic cells associated with
scattered mitotic cells into the liver and spleen (Figure 2b).
Immunohistochemical staining using anti-mCD3 and hGFAP
antibodies was performed in 4% paraformaldehyde-ﬁxed spleen
and liver specimens of T98G-DDS10 xenograft mice containing
a tumor compared with the spleen and liver of the original
T98G xenograft mice. Immunohistochemical staining revealed
that the leukemic cells observed in the spleen and liver of
T98G-DDS10 xenograft mice were CD3-positive, but GFAP-
negative (Figure 2b), suggesting that the tumor had not relapsed
with human glioblastoma cells. We suggest that non-tumori-
genic T98G human glioblastoma cells become aggressive and
stimulate the induction of T-cell leukemia following long-term
hypoxia and nutrient starvation DDS.
Ampliﬁcation or insertion of a human oncogene can result in
the development of secondary leukemia. To examine whether
oncogenes derived from T98G-DDS10 cells were integrated
into the leukemic cells, PCR ampliﬁcation of the human
Alu-repetitive sequence, which is thought to be co-integrated
with ascertain human genes, was conducted using a spleen with
leukemic cells of T98G-DDS10 xenograft cachexia mice and
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mice. T98G cells and human cervix carcinoma HeLa cell
tumor from xenograft mice were used as standard and positive
controls of Alu-repeat. Ampliﬁcation of the human Alu-repeat
sequence was not detected in the mouse spleen with
leukemic cells, suggesting that mechanisms other than the
insertion of human oncogenes were involved in the develop-
ment of secondary leukemia (Figure 2c). Although the
T98G-DDS10 tumor cells injected in the mice were present
for a short period (Figure 1c), this affected the host cells
and caused leukemia. We hypothesize that the cytokines
secreted by T98G-DDS10 may be involved in the development
of leukemia. Increased expressions of inﬂammatory cytokines,
such as IL-4 and IL-6, often participate in the development
of leukemia.
8–10 Thus, we examined the expression of these
inﬂammatory cytokines in T98G-DDS10 cells compared
with the original T98G cells by quantitative real-time PCR
analysis. As expected, signiﬁcant upregulation of hIL-4 and
hIL-6 mRNA expression in T98G-DDS10 cells was observed
compared with the original T98G cells (Figure 2d). These results
suggest that IL-4 and IL-6, but not insertion of human DNA,
partially contributed to the development of CD3
þ T-cell
leukemia.
On the basis of these observations, we drew the conclusion
that long-term hypoxia and nutrient starvation stress cycles to
primary tumor cells can consequently stimulate leukemogenesis
independent of leukemogenic genetic chromosome aberra-
tions and mutation events by chemotherapy and radiotherapy.
Secondary leukemia, such as acute lymphocytic leukemia,
acute myeloid leukemia or myelodysplastic syndrome, is
reported to occur in patients with a history of chemotherapy
or radiotherapy of a primary solid tumor.
1,7 Our leukemic
model is independent of chemotherapy, but dependent on
hypoxia and nutrient starvation double stress. However, it is
possible that tumor cells located far from the existing
vasculature (central area of tumor mass) after chemo and
radiotherapy undergo hypoxia and nutrient starvation because
of disruption of the tumor vasculature. Expression of inﬂamma-
tion cytokines such as IL-6 has been reported to be upregu-
lated following chemo and radiotherapy.
10 Thus, hypoxia and
nutrient starvation in tumor microenvironments concomitant
with the induction of inﬂammation cytokines in tumors may be
important factors inducing the development of secondary
leukemia. However, infusion of human cytokines into nude
mice may not be sufﬁcient for the development of T-cell
leukemia, and other secretion factors or cell surface molecules
may also be involved in this process.
Antiangiogenesis suppressing the supply of both oxygen
and nutrients is an effective cancer treatment; however, after a
long-term treatment, tumors may become aggressive
4–6 and
may also affect host cells following antiangiogenesis, as shown
in our mouse models. To date, there is no clinical evidence
of secondary leukemia following antiangiogenesis therapy;
however, many newly developed antiangiogenic inhibitors
are currently undergoing clinical trials, which may show
more effective antiangiogenic and antitumor effects. To further
improve antiangiogenic therapy to overcome secondary prob-
lems, one approach is to eliminate double stress-resistant cancer
Figure 1 Recurrence of secondary tumor after remission of primary tumor in mice inoculated with hypoxic and nutrient-starved human
glioblastoma (T98G) cells. (a) Schematic diagram of hypoxia and nutrient starvation DDS cycle. T98G cells were cultured under hypoxia (1% pO2)
and nutrient starvation (nutrient deprivation medium containing 1% of nutrition according to composition of DMEM supplemented with 0.1% fetal
bovine serum) for 72h and recovered by culturing under normoxia in 30% nutrition for overnight, and then 100% nutrition for 24h until 80–90%
conﬂuence was achieved. This hypoxia and nutrient-starvation cycle was conducted for 10 or more cycles. (b) Hypoxia-induced cell death under
nutrient starvation. Relative cell growth of T98G cells was measured by sulforhodamine B (SRB) cell proliferation assay under the following
conditions: normoxia (control), hypoxia (1% pO2) supplemented with full nutrition (100% nutrition), nutrient starvation (1% nutrition) and hypoxia
and nutrient starvation DDS for 72h. (c) Volumes of primary tumor of T98G and T98G-DDS10 subcutaneously injected in BALB/c nu/nu nude
mice (n¼5). (*Po0.05, calculated using Student’s t-test). (d) In situ pictures of spleen and lymph nodes (blood from abdominal cavity) in mice
show secondary tumor.
Letter to the Editor
2
Blood Cancer Journalcells to inhibit the recurrence of the primary tumor, and also to
inhibit inﬂammatory cytokines to prevent secondary tumors
following remission of the primary tumor.
Only a very limited number of animal models of leukemo-
genesis are available. Our modelFin which aggressive tumor
cells induced leukemia in mice, independent of radiation and
Figure 2 Upregulation of IL-4 and IL-6 gene expression in T98G-DDS10 cells and development of CD3þ T-cell leukemia. (a) Quantitative real-
time PCR analysis of secondary tumor tissue against human b-actin, human GFAP, mouse CD3 and mouse CD19 mRNAs. (n¼3) (**Po0.01).
complementary DNA obtained from T98G was used as a positive control for human mRNA. (b) HE staining and immunohistochemical staining of
spleen and liver from original T98G and T98G-DDS xenograft mice against CD3 and GFAP antibodies (Red) with To-Pro-3 nuclear staining (Blue).
(c) Secondary leukemia does not contain human DNA at detectable levels. Detection of human DNA using Alu PCR assay on agarose gel following
30–40 cycles of PCR ampliﬁcation. DNA obtained from cultured T98G cells was used as standard control (using 1–500ng DNA and ampliﬁed for
30 cycles). DNA from HeLa xenograft tumor was used as a positive control for the ampliﬁcation of human DNA in spleen samples of T98G
xenograft and T98G-DDS10 xenograft mice (using 50ng DNA and ampliﬁed for 40 cycles). M, 100bp marker; NC, negative control. (d) T98G
signiﬁcantly upregulates expression of inﬂammation cytokines such as IL-4 and IL-6 following long-term hypoxia and nutrient deprivation double
stress. Quantitative real-time PCR analysis was carried out to examine the mRNA levels of hIL-2,h IL-4,h IL-6 and hIFN-g in T98G-DDS10 cells
compared with the original T98G cells. (*Po0.05; **Po0.01).
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characterizing the molecular mechanisms underlying leukemo-
genesis.
In conclusion, human glioblastoma cells survived long-term
hypoxia and nutrient starvation participated in the induction
of CD3þ T-cell secondary leukemia in mice after a complete
remission of the primary tumor xenograft, and independent
of chemo and radiation treatments. Taken together, our results
indicate that activated cancer cells exposed to hypoxia and
nutrient starvation after anticancer therapy can affect the host
microenvironment. Thus, targeting cancer cells resistant to
hypoxia and nutrient starvation is important to develop novel
cancer therapies and also to prevent secondary leukemogenesis.
Our animal model system may be useful for elucidating the
mechanism underlying hematopoietic malignancies.
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